Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5182072 | 0.82 | ALDH1A1 (0.42) | MAPTSMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL209159 | 0.75 | KMT2A (0.48) | KMT2AMEN1NPC1ALOX15RAB9A | |
| SCHEMBL28787804 | 0.74 | CHRM5 (0.73) | CHRM5CHKAMAPTSMN1; SMN2KMT2A | |
| SCHEMBL348708 | 0.74 | KCNA5 (0.43) | HTT | |
| SCHEMBL2091671 | 0.73 | ALDH1A1 (0.52) | MAPTSMN1; SMN2KMT2AMEN1ALOX15 | |
| SCHEMBL2090723 | 0.71 | CYP2A6 (0.38) | MAPTALOX15RAB9AKDM4EHTT | |
| SCHEMBL2096457 | 0.71 | ALDH1A1 (0.45) | CHKAMAPTALOX15RAB9AKDM4E | |
| SCHEMBL2096895 | 0.71 | APP (0.43) | MAPTSMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL7826817 | 0.71 | APP (0.43) | MAPTSMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL2099515 | 0.71 | APP (0.43) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | claimed |
| JP-2002539201-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2024071216-A1 | PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8017612-B2 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7538084-B2 | Cyclosporins | AMR TECHNOLOGY, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20040235716-A1 | Novel cyclosporins | CURIA GLOBAL, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004082629-A2 | NOVEL CYCLOSPORINS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| EP-0636141-B1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LTD (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-5441960-A | 1-pyrimidinylacetamide human leukocyte elastate inhibitors | ZENECA LIMITED (GB) | 1995-08-15 | — | — | US | disclosed |
| EP-0636141-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS. | ZENECA LTD (GB) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021210-A1 | PYRIMIDINYL ACETAMIDES AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | CHRM5 708/4885CHKA 3222/4885MAPT 4236/4885 |
| US-20040235716-A1 | Novel cyclosporins | CHP1, IL2, CCR1 | CHRM5 4622/4885CHKA 3183/4885MAPT 4409/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | CHRM5 4810/4885CHKA 2915/4885MAPT 3695/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | CHRM5 674/4885CHKA 3204/4885MAPT 4248/4885 |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CHRM5 4836/4885CHKA 1655/4885MAPT 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.